Matching articles for "Leukoencephalopathy"
Issue 1204 · March 14, 2005 Free
In Brief: Natalizumab (Tysabri) Withdrawn

The February 14th issue of The Medical Letter reviewed natalizumab ( Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in…

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):21
The February 14th issue of The Medical Letter reviewed natalizumab ( Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease (www.fda.gov) .